Included Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Included Health provides comprehensive health navigation and care delivery for employers, specializing in complex conditions, mental health, and LGBTQ+ healthcare needs.
About
Included Health is a digital health company formed through the 2021 merger of Grand Rounds Health and Doctor On Demand, creating a unified platform for health navigation and virtual care delivery for employer health plans. The company provides members with access to expert second opinions, specialist referrals, primary care, mental health services, and benefits navigation through a single integrated platform. Included Health has built specialized expertise in serving populations with complex care needs including members with serious diagnoses, those seeking LGBTQ+-affirming care, and employees navigating mental health challenges. The company raised over $300M and serves large self-insured employers as a comprehensive health benefit that supplements traditional insurance. The merger combined Grand Rounds' navigation and expert medical opinion capabilities with Doctor On Demand's virtual primary care and psychiatry platform, creating broader clinical coverage than either company offered independently. Included Health positions itself as a health equity platform that improves outcomes for all employees regardless of their health complexity, geographic location, or demographic characteristics.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.